PreciseDx

New York, United States

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.

$11.2M raised

Jun 2025

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has PreciseDx raised?

PreciseDx has raised $11.2M in total funding. The most recent round was Series B. The last funding was announced in June 2025.

Who are PreciseDx's investors?

PreciseDx's investors include Agilent Technologies, Quest Diagnostics, LabCorp, Mount Sinai Health System, Eventide.

Where is PreciseDx headquartered?

PreciseDx is headquartered in New York, United States.

What does PreciseDx do?

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.

What stage is PreciseDx at?

PreciseDx is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 5, 2025.

MLA

"PreciseDx — Funding & Investors." VCBacked, June 5, 2025, https://www.vcbacked.co/company/precisedx. Accessed July 6, 2026.

APA

VCBacked. (2025). PreciseDx — Funding & Investors. Retrieved July 6, 2026, from https://www.vcbacked.co/company/precisedx

Wikipedia (cite web)

{{cite web |title=PreciseDx — Funding & Investors |url=https://www.vcbacked.co/company/precisedx |website=VCBacked |access-date=July 6, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 5, 2025.